Purpose and Audience
It is vital that Medical Science Liaisons (MSLs) supporting scientific exchange around left atrial appendage closure (LAAC) devices in nonvalvular atrial fibrillation (AF) are knowledgeable and confident in the science and products they work with. Here, we intended to help MSLs (1) understand the disease state and the therapeutic rationale, (2) command the key clinical evidence, (3) anticipate the questions Health Care Providers (HCPs) commonly raise, and (4) communicate the data in a balanced, non-promotional manner consistent with the MSL role.
Part 1: The Disease State
Why atrial fibrillation and stroke risk matter?
Atrial fibrillation is the most common sustained cardiac arrhythmia in older adults and carries substantial morbidity and mortality (Tynes et al, 2026). The core clinical driver of LAAC interest is stroke risk: AF increases the risk of ischemic stroke roughly fivefold and contributes to approximately 20% of all ischemic strokes (Zimetbaum, 2017). Because most AF-related thrombi originate in the left atrial appendage (LAA), the appendage is a logical anatomic target for mechanical stroke prevention (Hijazi & Saw, 2022).
MSL talking point: Framing conversations around stroke prevention as the shared clinical goal, rather than around a device, keeps exchanges scientific and patient-centered.
The current standard of care
Chronic oral anticoagulation remains the guideline-based standard for stroke prevention in AF. MSLs should be fluent in the mechanisms:
- Vitamin K antagonists (warfarin) require INR monitoring and have significant food/drug interactions (Hull et al., 2019).
- Direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban act as factor Xa inhibitors, preventing thrombin generation and fibrin clot formation (Hull et al., 2019).
Risk stratification typically uses the CHA₂DS₂-VASc score, where higher scores indicate greater stroke risk and a stronger indication for anticoagulation (Melgaard et al., 2020).
Balanced framing for the field: Anticoagulation is effective but has real-world limitations such as bleeding risk, monitoring burden, cost, drug interactions, and adherence challenges. LAAC is not a replacement for anticoagulation in all patients; it is an alternative strategy for selected patients, particularly those with contraindications to, or difficulty tolerating, long-term anticoagulation (Kumar, 2022). MSLs should resist any framing that overstates LAAC’s role beyond the studied populations.
How LAAC works
LAAC devices mechanically isolate the LAA, reducing the likelihood of embolic stroke from appendage thrombus (Hijazi & Saw, 2022). The most widely used device, the WATCHMAN FLX, is deployed via a transseptal approach and functions as a mechanical barrier to thrombus formation within the LAA (Leon et al., 2020).
Part 2: Key Evidence
MSLs should be able to summarize each pivotal trial accurately, including its design, population, endpoints, and limitations. The table below is a quick-reference framework.
| Trial | Focus | What it tells us | Key limitations to acknowledge |
| PROTECT AF | First-generation WATCHMAN vs. warfarin | Established non-inferiority concept for LAAC | Early-generation device; higher procedural complication rates |
| PREVAIL | WATCHMAN vs. warfarin (confirmatory) | Improved procedural safety over PROTECT AF | Efficacy endpoints did not all reach non-inferiority margins |
| PINNACLE FLX | Next-generation WATCHMAN FLX safety/efficacy | Reported effective LAA closure with low adverse event rates (Kar et al., 2021) | Single-arm design; no randomized comparator |
| CHAMPION-AF | WATCHMAN FLX vs. DOACs | Directly addresses the DOAC-era comparison HCPs ask about (Leon et al., 2020) | Ongoing/comparative context; interpret endpoints as reported |
| Amulet IDE | Amplatzer Amulet vs. WATCHMAN | Head-to-head device comparison (Lakkireddy et al., 2021) | Interpret device differences within trial-defined endpoints |
Framing the individual studies
- PINNACLE FLX evaluated the next-generation WATCHMAN FLX and reported effective LAA closure with low rates of adverse events (Kar et al., 2021).
- MSL note: This was a single-arm study — a critical caveat to state proactively, since it lacks a randomized comparator.
- Amulet IDE was a randomized controlled trial comparing the Amplatzer Amulet occluder with the WATCHMAN device for stroke prophylaxis (Lakkireddy et al., 2021).
- MSL note: This is the appropriate source when an HCP asks for head-to-head device data; direct them to the trial-defined endpoints rather than to summary characterizations.
Part 3: Handling the Device
HCPs frequently ask MSLs, “Which device is better?” This is where disciplined, non-promotional communication matters most.
Avoid categorical superiority language. Statements that one device demonstrates “superior outcomes” overall are not appropriate for MSL exchange unless they precisely reflect a specific, pre-specified endpoint met in a well-powered comparative trial. The more accurate and defensible framing is:
- The Amulet IDE randomized trial provides the head-to-head data between Amplatzer Amulet and WATCHMAN; MSLs should point HCPs to the specific endpoints (e.g., safety, efficacy, and closure endpoints) as reported and describe results within those pre-specified terms rather than as a global verdict (Lakkireddy et al., 2021).
- The WaveCrest device remains under investigation and is not currently approved for use in the United States — an important factual boundary for field discussions (Hijazi & Saw, 2022).
Suggested MSL phrasing:
“In the Amulet IDE randomized trial, the two devices were compared across pre-specified safety and efficacy endpoints. I’d be glad to walk through how each endpoint was defined and what the trial reported, so you can weigh that against your specific patient population.”
This approach shares evidence, respects the HCP’s clinical judgment, and avoids promotional overreach.
On device technology evolution
MSLs may field questions about newer iterations. The WATCHMAN FLX Pro received FDA approval in September 2023, with reported enhancements including improved visualization markers, a polymer coating, and expanded sizing options (Boston Scientific, 2023). MSL note: Present these as design features with a plausible mechanistic rationale and clearly distinguish engineering enhancements from demonstrated clinical outcome improvements, which require dedicated outcome data.
Part 4: Anticipated HCP Questions and Balanced Responses
“Should LAAC replace anticoagulation for my AF patients?”
No, anticoagulation remains the standard of care. LAAC is an alternative for selected patients, especially those with contraindications to anticoagulation, prior bleeding, or high fall risk (Kumar, 2022). Emphasize appropriate patient selection over broad substitution.
“What’s the advantage over lifelong DOACs?”
Anticoagulation requires ongoing adherence and carries a persistent bleeding risk, including intracranial hemorrhage. LAAC is a one-time procedural intervention that may reduce or eliminate long-term anticoagulation needs in appropriate patients (Kumar, 2022). Balance this by noting procedural risks and the importance of comparative data such as CHAMPION-AF (Leon et al., 2020).
“What are the procedural risks?”
Direct HCPs to trial-reported rates of pericardial effusion, device embolization, and bleeding, and frame them within each study’s population and follow-up period rather than as isolated numbers.
“What long-term data exist?”
Acknowledge candidly that longer-term and comparative outcome data continue to accumulate, and that some pivotal data (e.g., PINNACLE FLX) come from single-arm studies. This honesty strengthens MSL credibility.
Part 5: Principles for Non-Promotional Communication
- Lead with the clinical question, not the product.
- State study limitations proactively — single-arm designs, endpoint definitions, approval status.
- Avoid superlatives (“superior,” “best”) unless tied to a specific, pre-specified, met endpoint.
- Distinguish device features from proven outcomes.
- Reinforce guideline-based standard of care and appropriate patient selection.
- Defer clinical decisions to the HCP, offering evidence as a resource.
Conclusion
For MSLs, the value proposition of LAAC lies not in declaring a winner among devices or displacing anticoagulation, but in helping HCPs interpret a rapidly evolving evidence base for the right patients. The data — from PROTECT AF and PREVAIL through PINNACLE FLX, Amulet IDE, and CHAMPION-AF — support LAAC as a meaningful alternative to chronic oral anticoagulation in selected nonvalvular AF patients, particularly those at high bleeding risk or with anticoagulation contraindications. Anticoagulation remains the standard of care, and continued long-term and comparative research will further define LAAC’s role. MSLs who communicate this evidence accurately, acknowledge its limits, and keep the exchange scientific rather than promotional will be the most trusted partners to their HCP audiences.
References
Boston Scientific. (2023, September 6). Boston Scientific announces FDA approval for the latest-generation WATCHMAN FLX™ Pro left atrial appendage closure device [Press release]. https://news.bostonscientific.com/2023-09-06-Boston-Scientific-Announces-FDA-Approval-for-the-Latest-Generation-WATCHMAN-FLX-TM-Pro-Left-Atrial-Appendage-Closure-Device
Hijazi, Z. M., & Saw, J. (2022, December 2). Atrial fibrillation: Left atrial appendage occlusion. UpToDate.
Hull, R. D., Garcia, D. A., & Vazquez, S. R. (2019). Warfarin and other VKAs: Dosing and adverse effects. UpToDate, Waltham, MA.
Kar, S., Doshi, S. K., Sadhu, A., Horton, R., et al., PINNACLE FLX Investigators. (2021). Primary outcome evaluation of a next-generation left atrial appendage closure device: Results from the PINNACLE FLX trial. Circulation, 143(18), 1754–1762. https://doi.org/10.1161/CIRCULATIONAHA.120.050117
Kumar, K. (2022, December 1). Atrial fibrillation: Overview and management of new-onset atrial fibrillation. UpToDate.
Lakkireddy, D., Thaler, D., Ellis, C. R., Swarup, V., Sondergaard, L., Carroll, J., Gold, M. R., Hermiller, J., Diener, H. C., Schmidt, B., MacDonald, L., Mansour, M., Maini, B., O’Brien, L., & Windecker, S. (2021). Amplatzer Amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): A randomized, controlled trial. Circulation, 144(19), 1543–1552. https://doi.org/10.1161/CIRCULATIONAHA.121.057063
Leon, M., Ellenbogen, K. A., Doshi, S., & Kar, S. (2020, May 19). Champion-AF clinical trial (CHAMPION-AF). Boston Scientific Corporation. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04394546
Melgaard, L., Overvad, T. F., Jensen, M., Lip, G. Y. H., Larsen, T. B., & Nielsen, P. B. (2020). Thromboembolic risk in non-anticoagulated patients with atrial fibrillation and valvular heart disease. JACC: Clinical Electrophysiology. https://www.jacc.org/doi/10.1016/j.jacep.2020.07.005
Tynes, J., Collier, K., Pisano, S., Walgren, E. & Kuriakose, V. (2026). A Systematic Review of Left Atrial Appendage Closure Device Efficacy and Safety in Comparison to Chronic Anticoagulation in the Setting of Nonvalvular Atrial Fibrillation. International Journal of Science and Innovation Engineering. Vol. 3. Issue 4. Pgs. 1383 -1389. April 2026. https://ijsci.com/paper-details.php/01557938
Zimetbaum, P. (2017, March 7). Atrial fibrillation. Annals of Internal Medicine, 166(5), ITC33–ITC48. https://doi.org/10.7326/AITC201703070
About the authors:

Jerrod Tynes, MS, MEd, MSIS, CCHW
Jerrod Tynes serves as an Assistant Professor for West Coast University – Texas in Richardson, Texas. He has extensive experience in higher and K-12 education, and he has spent years developing and spearheading various new science programs. An active researcher, he has a few varied publications in health care ranging from patient care and venom bites to medical insurance and health care burnout. He is passionate about creating a generation of strong critical thinkers in health care. When he is not working, he spends time with his family, is training for a run, selling homes as a real estate agent, or breeding and caring for snakes in his reptile room.

Kailey Collier, MPAS, PA-C
Kailey Collier serves as an Emergency Medicine Physician Assistant for Envision Physician Services in Plano, Texas. She was a member of the inaugural class of the West Coast University – Texas MPA program. She is passionate about serving her community and increasing health outcomes throughout North Texas.

Shyann Pisano, MPAS, PA-C
Shyann Pisano serves as a Physician Assistant for Momentum Spine and Joint in Dallas, Texas. She was a member of the inaugural class of the West Coast University – Texas MPA program. Prior to her time as a PA, she served as a medical scribe for ENT Specialty Partners and was a Certified Nursing Assistant for Foursquare Healthcare. When not with patients, she enjoys coaching volleyball for Victory Volleyball Club in Plano.

Ellen Walgren, MPAS, PA-C
Ellen serves as an Emergency Medicine Physician Assistant for Envision Physician Services in Plano, Texas. She was a member of the inaugural class of the West Coast University – Texas MPA program. Prior to her time as a PA, she gained varied healthcare experience as a certified clinical medical assistant, an ER patient care technician, and ER medical scribe.

Chantelle Lessard-Chaudoin, DMSc, MPH, MMS, PA-C
Dr. Chantelle Lessard-Chaudoin serves as the Founding Program Director for the Master of Science in Physician Assistant Studies program at SCU’s Phoenix, Arizona campus. An Associate Professor with extensive experience in physician assistant education, public health, and clinical practice, she has contributed to the development of innovative residential and online graduate programs designed to support diverse adult learners through integrated educational technologies. A practicing Family Medicine Physician Assistant, Dr. Lessard-Chaudoin specializes in primary care and clinical research, with a commitment to delivering comprehensive, patient-centered care. Her educational philosophy centers on evidence-based teaching that prepares future physician assistants to provide compassionate, collaborative, and high-quality healthcare while emerging as leaders within the profession.
Dr. Lessard-Chaudoin is a dedicated advocate for health equity and whole-person care, aligning closely with SCU’s mission to improve the health and well-being of individuals and communities. Her scholarly interests include mental health among healthcare professionals, interprofessional education to support team-based care, and global preventive health initiatives. She holds a Doctor of Medical Science in Leadership, a Master of Medical Science in Physician Assistant Studies, a Master of Public Health in Community Health Education, and a Bachelor of Science in Health and Physical Education.
Outside of academic and clinical practice, she enjoys exploring Arizona and traveling internationally with family and friends, embracing opportunities to learn from diverse cultures and perspectives.

Katie Steinmeier, MSM, PA-C, BSN, RN
Katie Steinmeier is a physician assistant with over 12 years of experience. She has over 3 years of experience in PA education, starting at the WCU – Texas program and eventually landing at the West Coast University Center for Graduate Studies. As a Physician Assistant, she has worked for Texas Hand and Arm Center, Care Now, and Plano Orthopedic Sports Medicine and Spine Center. She is passionate about educating the next generation of providers.
Have an opinion on this article? Send a message to the editor.